Background: HIV-associated neurocognitive disorder (HAND) may appear in patients with viral and immunological response to treatment and remain unnoticed during the initial stage of the infection. The goal of this study is to evaluate the development and/or progression of HAND in patients with undetectable viral load for more than ten years. Methods: We included adult HIV-infected patients who were under antiretroviral treatment and had undetectable plasma viral load for more than ten years (blips were included). These patients had already been subjected to neurocognitive evaluation five years previously. Demographic, clinical and analytical data were analysed. For the neurocognitive evaluation, the WAIS-III subtests (digit symbol coding and symbol search), trail making test (TMT) A and B, Stroop test and categorical verbal fluency (animals) tests were used. SPSS® version 22.0 for Windows was used for statistical analysis. Results: In this re-evaluation, performed 4.76 (±1.82) years after the first one, 9 (36%) patients showed deficits in processing speed (WAIS-III and TMT A), 8 (32%) executive function (TMT B and Stroop) and 12 (48%) verbal fluency. There were significant statistical differences between the past and current executive function tests (p = 0.029 and p = 0.01), highlighting worsening of deficits. No differences were found for the other tests. No association was found between deficit progression and the studied variables. Conclusions: Although not generally noticed on regular appointments, in this small population, worsening of executive function deficits (mental flexibility and divided attention) was found. Classical risk factors for HAND did not appear to interfere in its progression. Speed of 
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Introduction
Since the discovery of the human immunodeficiency virus (HIV) and the first descriptions of the acquired immunodeficiency syndrome (AIDS), more than 30 years ago [1] [2] [3] , major advances in diagnosis and treatment were made.
However, HIV-associated neurocognitive disorder (HAND) [4] continues to be a spectrum of neuropsychological manifestations difficult to characterize and for which the benefit of antiretroviral therapy (ART) hasn't been determined [5] .
Several cross-sectional studies state that half of HIV-infected patients have some form of cognitive impairment [6] [7] , and AIDS patients score consistently worse than healthy controls [8] [9] . Although severe forms are now rare, milder forms remain common and usually unnoticed [10] . These deficits can have a major impact on the ability to perform daily tasks and on quality of life [10] [11].
The spectrum of HAND is wide, so in 2007 the criteria of Frascati were established to distinguish three subclasses of increasing severity in terms of cognitive and functional status: asymptomatic neurocognitive impairment, mild neurocognitive disorder, and HIV-associated dementia [12] . These disorders and their degree of impact are influenced by biological factors related to HIV and chronic infection neurodegeneration [13] There are several comparative cross-sectional case-control studies, but few longitudinal studies to assess the development of neurocognitive status in patients with HIV infection and risk factors such as immune, viral and clinical status or combined therapy may have in HAND. The Portuguese population has a particular context: most of HIV-infected patients have low education and socio-economic level [20] , but have access to ART, medical and psychological care free of charge and, as a result, great adherence and positive developments on morbidity and mortality are registered.
Since the impact of ART seems irrelevant related to HAND development, we proposed to carry out the second neurocognitive evaluation in patients on ART with suppressed viral load for 10 years, assess their cognitive and functional evolution, and evaluate the impact of biological, psychological and social variables.
Methods
The study of neurocognitive function of HIV patients followed in the Infectious Diseases Department of São João Hospital Centre, in Oporto, is a continuous longitudinal analysis previously approved by the hospital's Ethics Committee.
Fifty nine of suppressed patients evaluated for the first time in 2008 [21] were summoned for a second neurocognitive evaluation between January and June 2014. Twenty-five patients agreed to be subjected again to psychological evaluation. All these patients were on ART and had viral suppression for over 10 years.
Patients with history of blips were also included. Data processing and statistical analysis was performed using the SPSS® version 22.0 for Windows operating system. The existence of a statistical relation between the results obtained in the current psychological tests and those five years before using simple linear regression was firstly assessed. Then, whether there was a statistically significant difference between these results using the T test for paired samples. Different demographic, clinical, analytical and psychological variables (T test for independent samples and X2 test for a 5% significance level) were then tested for correlation.
Results
Out of the 25 evaluated patients (Table 1) Regarding ART at the second neurocognitive evaluation, 22 patients (88%)
were under triple therapy. The most used backbone was emtricitabine/tenofovir (FTC/TDF), in 12 patients, 7 were on abacavir/lamivudine (ABC/3TC) and 3
were on zidovudine/lamivudine (AZT/3TC). Mean ART CNS penetration score was 7.68 (±1.35).
Seven patients (28%) had AIDS, and none had a previous history of CNS 
Discussion
The impact of HIV infection in the CNS has been described since the beginning of the epidemic. In Portugal, there is insufficient data about the effects of HIV infection on neurocognitive impairment. Thus the importance of these studies:
to characterize the Portuguese population and highlight the diagnosis difficulty of HAND on consultation and its associated morbidity. The difficulty of diagnosis is also based on its clinical variability: patients may show signs of cognitive recovery with ART or signs of escalation with the disease progression; they can either present a static or a fluctuant course [9] .
In our study, only executive function presented a significant direct association with the first performance, and a clear cognitive deterioration was found in this domain. Executive function includes organizing capacity and a behavioural answer to solve a complex problem, remote memory activation, independent behaviour and adaption capacity in different contexts through verbal skills. These deficits are associated to frontal lobe lesion [24] and previous studies seem to demonstrate that this is the main cognitive domain affected by the HAND spectrum [25] .
Processing speed and verbal fluency tests haven't scored statistically different between evaluations, so a linear correlation wasn't demonstrated. This means that any existing fluctuation in these domains was probably due to external factors and not because of HIV infection or its therapy.
When variables age, AIDS, CD4+ count, schooling, ARV CNS penetration score, blips, depression or other CNS disease, disease evolution (years) or time to supressed viral load (months) were analysed, no statistically significant association with the clear executive function deterioration was found. However, there seems to be a tendency for patients with longer duration of disease to present a more evident impairment (Stroop; p = 0.07), and the same can be said to pa-tients with depression (TMT-B; p = 0.132). Otherwise, in our sample, female sex was associated with less severe worsening, given that only one woman had executive function impairment, against 9 men (TMT-B; p = 0.025).
These results may be due to sampling limitation. It's possible that with a larger sample, the influence of duration of disease and cognitive decline would be unequivocal and, on the contrary, there wouldn't be any difference between sexes.
Reasons 
Conclusions
Albeit the progress of HIV treatment and a subsequent higher survival, patients still have a risk of neurocognitive degeneration, and its evolution isn't detectable in a usual appointment. In this small sample we found worsening of executive function (mental flexibility and divided attention) that is not related to immune recovery, adherence, response to treatment or other clinical hotspots usually highlighted during consultation.
Risk factors classically associated to HAND don't seem to interfere with its progression. More longitudinal studies with larger samples, with a more heterogeneous population and with a wider array of psychological tests are welcome in order to further validate, or refute, our findings, as well as to better characterize the way in which HAND progresses.
